Treatment of myelofibrosis in younger patients: To transplant or not?

American Journal of Hematology

Volumn 84, Issue 3, 2009, Pages 131-132

  Jabbour, Elias ^a   Verstovsek, Srdan ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INCB 018424; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; LG 101348; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; TG 101348; UNCLASSIFIED DRUG; XL 019;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; ENZYME INHIBITION; HUMAN; MYELOFIBROSIS; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT INDICATION;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY MYELOFIBROSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 62949103793     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21368     Document Type: Note

References (19)

1. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: Analysis based on 334 patients from a single institution. Cancer 2007;109:2083-2088.
2. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003;102:3912-3918.
3. Dupriez B, MorelL P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
4. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997;973:635-640.
5. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: Clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001;73:194-198.
6. Samuelson SJ, Sandmaier BM, Heslop HE, et al. Allogeneic hematopoietic cell transplants in patients with myelofibrosis age 60 and older. Blood 2008;112:2798.
7. Siragusa S, Passamonti F, Cervantes F, Tefferi A. Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients. Am J Hematol 2008, Dec 2, Epub ahead of print.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
9. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365: 1054-1061.
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
11. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
12. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-22792.
13. V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 2005;131:320-328.
14. V617F expression in murine hemato-poietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652-1660.
15. V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-4281.
16. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
17. Verstovsek S, Kantarjian HM, Pardanani AD, et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETMF). Blood 2008;112:1762.
18. Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 2008;112:98.
19. Pardanani AD, Gotlib J, Jamieson C, et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood 2008;112:97.